Biomedicine in Navarra 2010

Biomedical Cluster in Navarra

indexOverview > TheregionofNavarra 5 >TheBiomedicalsector 7

> Highlights 7> Products,ServicesandTechnologies 9> MapoftheBiomedicalsector 11

Biomedical cluster description >

Companies 14 > > Productdevelopmentcompanies 14Supportservicecompanies > 19

UniversitiesandResearchCenters 26 >Supporthealthcarecenters 33 >Promotingagents 34 >Biotechnologicalcorefacilities 40 >

Biomedicine in Navarra // December 2010

Biomedical Cluster in Navarra

Overview


Pamplona

The region of Navarra 5


Navarra is a strong industrial region that is thehometosomemajorcompanies inthesectorsofRenewableEnergies,BioTech,Automotion&FoodProcessing, and it hosts over 120 multinationalcompanies. Indeed, Navarra is a worldwide lea-der in technologicaldevelopmentandproductionintheRenewableEnergiessector,andtoday65%oftheelectricityconsumedinNavarracomesfromrenewablesources. Inaddition, theregionboastsone of the most productive car manufacturingplants in theworldandavegetable food industrywhichisrenownedforhishighquality.

AmongthemostimportantassetsinNavarraisitswell-balanced productive structure, its excellentgeographicalpositionanddegreeofinternationali-zation,aswellasitsgoodinfrastructure.NavarraisoneoftheSpanishregionswiththebestnationalindicatorsintermsofsocialwelfare,accesstoservicesandqualityoflife.WithaGiniindexof28andanOCDEhumandevelopment index (HDI)of0.97,Navarraisoneoftheregionswiththehighestqualityoflifeworldwide.

Throughoptimalandstableeconomicdevelopment,Navarra with a Gross Domestic Product (GDP)of 18,721M€ (INE2009) representing 1.9%ofSpain’sGDP,belongstothegroupofSpanishre-gionsthatregisterthebesteconomicindicators.IntermsofGDPpercapita,Navarraliesin32ndposi-

tioninthelistof271Europeanregions,withaGDPpercapitaof29,598euros.

Navarraiscurrentlyoneofthemostinnovativere-gionsinEuropeanditisaleaderinpromotingR&D,with itsgrowing investment inR&Dsupportedes-peciallybytheprivatesector.TheregionhadaR&DexpendituretoGDPratioof2.13%in2009,thebestofall the regions inSpain,with theprivatesectorrepresenting69%ofthetotalR&Dexpenditure.

Navarra is also the home to important researchandhighereducationcenters (PublicUniversityofNavarra,UniversityofNavarra,SpanishOpenUni-versity) and to 17 Research Centers. In terms ofqualifiedpersonnelintechnologicalandinnovativedisciplines,theregionranks19thinEuropeanditisrenownedforitsrangeintermsofhighereducation.Moreover,36%ofthepopulationbetween25and64yearsofagehaspassedthroughhighereduca-tioninNavarra,whichisreflectedintheavailabilityofhighlyqualifiedprofessionalsintheregion.

Theregionaladministrationisproudofitshighlevelofself-government,whichenablesittoadaptitspo-liciestothespecificdevelopmentstrategiesoftheregion.Moreover,Navarra´sgovernmentpromotesaflexibleandcloserelationshipwiththebusinesseslocatedintheregion.

The Region: Navarra is currently one of the most

innovative regions in Europe and it is a leader

in promoting R&D

TheregionofNavarra,the“ComunidadForaldeNavarra”,islocatedinthenorthofSpain,atthewesternfootofthePyrenees,whereitsharesa163kilometerstretchofthefrontierwithFrance.ThepopulationofNavarra,630,578inhabitants(NationalStatisticsInstitute-INE,2008),represents1.4%oftheSpanishpopulationandcoversanareaof10,421km2.

The region of Navarra

Biomedical Sector 7


HighlightsNavarraisemergingasoneofthemostdynamicBiomedicalclustersinSpainandoffersexcitingopportu-nitiesforinvestmentandpartnershipinthissector,particularlysince:

The Biomedical sector

Itboastsinnovationinfrastructurethatisamong >thebestinSpain.CIMA is the largestprivateBiomedical research >CenterinSpainanditattractsmorethan400re-searchers fromover 20 countries, representinganannualinvestmentofover20millioneuros.Navarra´s Biomedical cluster is home to some >ofthemostattractiveSpanishBiomedicalcom-panies, such as Digna Biotech, the companywiththelargestproductdevelopmentpipelineinSpainor3PBiopharmaceuticals, the firstCMOinSpain,aswellasCINFA,theleaderingenericmedicinesalesinSpain.There are five products that have been disco- >veredatinstitutionsinNavarraalreadyatdifferentstagesofclinicaldevelopment.Investmentishandledbyahighlyskilledandta- >lentedregionalpeople.Thanks to their tightly coordinated and net- >worked activity, the biomedical companies andinstitutionsofNavarracandevelopabiomedicalproduct throughall thenecessary stages, fromitsdiscoverytoitscommercialization.

Biomedical scientific research in Navarra has alongstanding tradition that has been developedaroundtheUniversityofNavarraandtheSchoolsofMedicine,SciencesandPharmacy.Thereareover1,000professionalsworkinginthissector,thenum-berofemployeeshavingdoubledoverthepast10yearsatarateof4.8%peryear.Moreover,over60patentshavebeenawardedduringthisperiod.

TheBiomedicalclusterwasinitiallycreatedaroundtheCenter for AppliedMedical Research (CIMA),inwhichmost of thebiomedicalR&Dcarriedoutat theUniversity of Navarra is undertaken, and agroupof companies emerging from this initiative.Thisclusterhasexpandedinrecentyears,asmorerecently developed new business initiatives haveemerged.

Accordingly, Navarra´s Biomedical cluster nowcomprisesover20privatefirmsandResearchCen-ters,manyofwhichhaveestablishedpartnerships

with government agencies, universities, teachinghospitals and technical colleges. Thehighqualityscientificresearchcarriedoutintheuniversities,inaffiliatedteachinghospitalsandmainlyinCIMAhaslaidthefoundationsforthesuccessofthemajorityofthecompaniesinthecluster.

Apart from these regional initiatives, Navarra hasdeveloped a wide range of collaborations withotherSpanishand internationalentities,suchthatnewprojectshavebeendevelopedintheregion,aswellasnewcompaniesthathavecommencedtheiractivitiesinNavarra.

Biomedical research in NavarraInNavarra,groundbreakingresearchiscarriedoutatnumerousCentersofExcellence.Theregion ishome to two prestigious universities with a long-standing academic tradition, a renowned publicand private healthcare network strongly linkedto the universities aswell as relevant agents thatpromoteappliedresearch,suchastheCenterforAppliedMedicalResearch(CIMA)andtheInstituteforAgroBiotechnology(IdAB).The biomedical research activity in Navarra con-tinues togrowwith theconstructionof newR&Dinfrastructures, like the Center for BiomedicalResearch (CIB)and theCenter forNationalMedi-cal Imaging,both initiativesof the regionalHealthDepartment to promote and complement thecurrently available Biomedical research offer inNavarra. In addition, there is considerable re-searchactivity innewlyemergentfieldssuchastheNanobiomedicalR&DactivitycarriedoutatL´Urederraand FideNa, both centers for Nanotechnologicalresearch, which complement and expand thepossibilities in biomedical research in the region.

Inaddition,Navarraishometoastronghealthser-vicesector,centeredaroundagroupofcommittedcollaborative institutions which are active in thisarea,aswellaspublicentitiesandcompaniesfromthefinancialsector.Theseorganisationsallpullto-gethertooptimizethedevelopmentpotentialofthesector.

8

Political innovation strategiesNavarra’s regional Government is highly commit-ted todevelopingandconsolidating theBiomedi-cal sector, and it has launched several initiativestopromoteR&DandInnovation intheregion, likeNavarra´sIIITechnologicalPlanorthe“MODERNAPlan”, a new knowledge-based economical deve-lopment model for the region. Moreover, the re-gionalgovernmenthaspromotedsome initiativesfocusedmorespecificallyonBiomedicine,likethe“Bionavarra”StrategyortheBiomedicalResearchStrategicPlan.

RegionalgovernmentalagenciesalsoplayacriticalandsupportingroleinthegrowthoftheBiomedicalclusterfromdifferentangles:The Society for the Development of Navarra >(SODENA)istheGovernmentofNavarra´smaininstrument for the region´s business develop-ment,withspecificfinancingandventurecapitalinvestedintheBiomedicalsector.The InnovationAgency ofNavarra (ANAIN) is a >public company created to promote a qualita-tiveandquantitativeincreaseininnovationwithintheregion.ANAINmonitorsandcoordinatesthestrategicdevelopmentplanspromotedbythere-gionalGovernment.

Financial support for InvestmentAtpresent,theoverallinvestmentintheBiomedicalsector inNavarra isabove300M€.Outof theseinvestments, about two thirds come fromprivateinvestorsandonethirdfromgovernmentalgrants.TherearenumerousgrantsavailableforR&Dpro-jects,providedbyNationalandRegionaltechnolo-gysupportprograms,thatincludebothnondilutivegrantsandlowinterestloans.

Private investors have played a key role in con-solidating the sector, accounting for over 64%ofthe overall investment in R&Dwithin Navarra, anamountthatistwiceasmuchtheaverageofprivateinvestmentinBiomedicalresearchinSpain.

Indeed,theregioniscurrentlyhometosomeofthemostrelevantSpanishinvestorsinBiotechnology,suchasSODENAthathasbecomeakeyelementintheconsolidationofthissector,withadirect in-vestment in most of the biomedical companiescurrentlyoperatingintheregion.Themainfinancialinstitutionintheregion,CajaNavarra(CAN),alsoin-vestsintheBiomedicalsectorthroughitsindustrialgroupCorporaccionCANanditinvestsbothinre-gionalBiomedicalprojectsaswellasotherprojects

elsewhereinSpain.Finally, other private investors, such as venturecapitalfirms likeClaveMayorandGenera21andotherfinancialinstitutions,likeCajaRuraldeNava-rra,playamajor role throughtheirparticipation inthemajorityof theentrepreneurial initiatives intheregion.In addition to private investment, public financialsupport,bothatanationalandregional level,hasbeen instrumental in providing funding, represen-ting 30% of the overall investment. For example,sincetheimplementationofNavarra´sIIITechnolo-gicalPlan(2008-2011),theGovernmentofNavarrahassupported39BiotechnologicalR&Dprojects,representing 33.5%of the overall budget appliedfor.

Workforce and educational Institutions Around1,000peopleareemployedinthelifescien-cesectorinNavarraandmostofthemareactiveintheareaofR&D.Indeed,thescientistsandtechni-ciansinNavarrareceiveoutstandingtraining.Navarra’sBiomedicalcluster issupportedbypro-grams and initiatives that are offered through anetworkofeducational institutions.TheUniversityof Navarra is internationally recognized for its ex-cellenteducationalquality,aswellasitsadvancedresearchfacilitiesandoutstandingachievementsintheBiomedicalfield.TheUniversityofNavarrahasthreeSchoolswhichareactiveintheareaofBiomedicine:theSchoolsofMedicine,PharmacyandSciences,withadiverseand highly specialized range of Degree, DoctoralandMaster Programs in this area. At this institu-tion,theMaster’sProgramintheResearch,Deve-lopmentandInnovationofNewDrugswasrecogni-zedasthebestMaster’sProgramofferedinSpaininthisfield.Moreover, in Navarra there are a wide range ofhighlyskilledAssociateDegrees/SeniorTechnician

Percentage funding to finance R&D expenditure in Biotechno-logy in Spain and Navarra (Navarra´s Statistics Institute-2007)

NavarraSpain

Public Private Foreing IPSFL

0

14

28

42

56

70

%

Biomedical Sector 9


ThediversitywithintheBiomedicalclusterinNavarraiscontinuouslyexpanding.Currently,thebiophar-maceuticalresearchfocusesonOncological,Neurological,Cardiovascular,Gastrointestinal,Ophthalmo-logicalandDermatologicaldiseases,withspecialstrengthinbiologicals,suchasrecombinantproteinsandgeneandcelltherapies,drugdeliverytechnologies,nanoparticleandpharmaceuticaldevelopment.

Products, services and technologies

Thebiopharmaceuticalfirmsareworkingwithmorethan 50 therapeutic and diagnostic products indifferentstagesofdevelopment.Someofthemoreadvancedproducts includeaproduct inPhase IIIofdevelopmentforthetreatmentofSclerodermia,skin cancer and actinic keratosis, aPhase II pro-duct to treatHepatitisCoraPhase Iproduct foruse in liver transplantsand resection.Allof theseproducts are currentlybeingdevelopedbyDignaBiotech.

Inaddition,CINFAistheleadinggenericscompanyin Spain and it offers a wide range of prescrip-tionandOTCproducts ina varietyof therapeuticareas.

Alongwith product development companies, theclusteralsohostsanumberofcompaniesofferingsupport services that include, but are not limitedto, protein production, pharmaceutical develop-mentandproduction,pharmacokineticsandphar-macodynamics modeling, dosage formulation,drug delivery and quality control and regulatoryassessment.

Navarra’sBiomedical cluster is supportedby topprivateandpublic researchand innovation infras-tructure.These facilitiesare the resultofstrategicregion-widepartnerships formed toencourage in-dustry growth (for further information, please seetheBiotechnologicalcorefacilitiessection).

training courses that are related to Biomedicine,ensuringthatspecializedtrainingisavailabletotheprofessionalsworkinginthissectoratalllevels.All in all, Navarra guarantees a steady supply ofhighlyqualifiedprofessionalsthatarereadytowork

in the fieldofBiomedicine at all levels.Moreover,thescientificandbusinessopportunities,togetherwithNavarra’s renownedqualityof life,attract re-searchersfromalloverSpainandbeyond.

10

SomeinfrastructuresincludeGenomicandProteo-micplatforms,clinicaltrialsitesforPhaseIclinicalstudies,state-of-the-artMedicalImagingtechnolo-giesthatrangefromMagneticResonanceImaging(MRI) to Positron Emission Tomography (PET),biobanks with different tissue and DNA samplesoranimalfacilitiestoprovideaccessforpreclinicaltesting.

Furthermore, Navarra´s Innovation Park providesan environmentwhere technology-based compa-niescansetup,growandperformallkindsofR&Dactivities.TheParkhasallthebasicelementsofaninnovationagency(technologicalcentersandcom-panies, access to universities, incubator space,etc),aswellasfirstclassinfrastructure.

ANAIN coordinates the activity of thePark and itcurrentlyworksinfourareas:EnergyandEnviron-ment, NanoBiotech, BioHealth and Technology-BasedInnovativeEnterprises(EIBTs).

TheBioHealthareaintheParkbringstogethermostofthehealthrelatedR&Dcenters,theUniversityofNavarraandtheregionalHealthcareSystem,alongwith established Biotech companies. The Nano-Biotecharea ishome toHealth relatedNanotechandAgroBiotechR&Dcentersand theTechnolo-gy-Based InnovativeEnterprise area (coordinatedbyCEIN -NavarraBusiness InnovationCenter-anincubatorthathousesmostoftheBiomedicalcom-paniesinthesector).ItisexpectedthatNavarrawillestablishaspecificBiotechnologicalincubatorareaintheforthcomingyears.

Navarra’sBiomedicalclusterisalsoworkingines-tablishinginternationalscientificandfinancialpart-nershipstohelpfulfillthepotentialcommercialbe-nefitsavailablefromthecutting-edgeR&Dandthepioneering intellectual property generated at theregion’sworld-classresearchinstitutions.

Biomedical Sector 11


Map

of t

he B

iom

edic

al s

ecto

rTh

ankstoatig

htnetworkedactivity,theBiomed

icalin

dustrialand

acade

miainstitutionsinNavarracollab

orateineachph

aseinthede

velopm

entof

pharmaceuticalprod

ucts,fromthebe

nchtothebe

dside.

Dru

g D

evel

OPM

eNT

PrO

ces

s

rese

arch

c

ente

rs a

nd

univ

ersi

ties

companies

Prod

uct

deve

lop-

men

t

supp

ort

serv

ices

Centrode

Imag

enMéd

ica

Mar

ket

>>c

linic

al s

tudi

esPr

eclin

ical

stu

dies

lead

opt

imiz

atio

nle

ad

iden

tifica

tion

& va

lidat

ion

Targ

et

iden

tifica

tion

& va

lidat

ion

CENT

RODEINVE

STIGAC

IÓNBIOMÉD

ICA

Biomedical cluster

description


14 companies // Product development companiescompanies // Product development companies

general descriptionBITA, thetradenameof“ProyectodeBiome-dicinaCIMAS.L.”,istheownerentityforallthepatents generated from the research carriedoutattheCenterforAppliedMedicalResearch(CIMA) in Pamplona. BITA is a biotechnologyfirmwhose purpose is to adequately protectthe intellectual property generated at CIMAand to exploit these through license agree-mentswith other firmsandcompanies in thebiotechnologyfield.From the very moment of its inception, thecompany commenced with some patentscontributed by one of its founder-members,the University of Navarra. Since then, therehasbeenanotable increase inthenumberoffindingsprotected,thankstotheefficiencyandproductivityoftheresearchatCIMA.DIGNABiotech,afirmthatalsobelongstotheCIMA-DIGNAProject, is a unit that acts as apreferentiallicenseeofthepatentsfromBITA.BITAcame intobeingas theconsequenceofajointventurebetweentheUniversityofNava-rra,ownerofCIMA,andagroupof15financialbackers.Theseincludedsomeofthemostim-portantcompaniesinSpain,aswellassomeofthemost representative regional entities fromNavarra,suchastheRegionalGovernmentofNavarra(throughitsarmforbusinessdevelop-ment,SODENA),theUniversityofNavarra,andthesavingsbanks,CajaNavarraandCajaRuraldeNavarra.BITAembracessomeofthelargestnationalcorporationsfromdifferentsectorsofthe national economy, such as, BBVA,CorteInglés,Fuertes IMásDS.L-GrupoFuertes (ElPozo), Loyalty Square S.L. which representsOmega Capital, Masaveu de InvestigacionesyDesarrolloS.L.,PontegadeaBiotecnológicaS.L.andUngríaPatentesyMarcas.

Priority areas Oncology, Neurosciences, Cardiovascular di-seases,GeneTherapyandHepatology.

Products, services and/or techno-logies Thecompanyownsover50patentsrelatedtotherapeuticanddiagnosticapproachesinOn-cology,Neurosciences,Cardiovasculardisea-ses,GeneTherapyandHepatology.

Achievements and future prospectsBITAhasachievedjointownershipandpatentmanagement agreements with organizationsfromallovertheworld,suchastheUniversityofNavarra(Spain),theUniversityofBarcelona(Spain),UniversityofAlabama(USA),Universi-tyofCalifornia (USA),UniversityofMinnesota(USA),UniversityofWashington(USA),PasteurInstitute(France),INSERM(France)andBorstelResearchCenter(Germany),amongothers.Moreover,BITAhassignedlicenseagreementswith several companies, such asDIGNABio-tech (Spain), 3P Biopharmaceuticals (Spain)andAmsterdamMolecularTherapeutics-AMT(TheNetherlands).

Avda.PioXII,22.Oficina131008Pamplona(Navarra)T(+34)[email protected]

contact PersonAntonioMartín(CEO)

BITA - Proyecto Biomedicina cIMA s.l.IPManagement >

Product development

2. Biomedical Cluster description 15


companies // Product development companiescompanies // Product development companies

support services

Product development

general descriptionWithover40 years’ experience,CINFAoffersone of the most complete formularies onthemarket with over 750 presentations. Thecompany’scapitalstockis100%Spanishandthe drugmanufacturing process is managedfrom start to finish at our head offices in Na-varra,fromthedevelopmentofthedrugtoitsmarketing through distributors and pharma-cies.AllthismakesCINFAtheleadingSpanishphar-maceutical companies in terms of volume ofsales through retail pharmacies, and Spain’ssecondleadingpharmaceuticalcompanyifweincludeinternationalcompaniesintheranking.Thecompanyhasmodernlaboratoriesandtwoindustrial sites equipped with the very latesttechnology, where more than 70 million pro-ductunitsaremanufacturedeveryyearunderthemostrigorousstandardsofqualitycontrol.Thecompanybeganitsactivityin1969,whenagroupofpharmacists ledbyEzequielLorcacreatedCINFA.Sincethen, thecompanyhasgrownsignificantlyandcurrently,CINFAisow-nedby2,600shareholdersacrossSpain.CINFAispresentinover30countriesworldwi-de,mainlyinFrench-speakingAfricaandLatinAmerica.CINFA also distributes andmarketsgenericmedicinesinPortugalthroughanagree-mentwith thepharmaceutical companyFaesFarma, and it has a marketing subsidiary inAlgeria.

Priority areas Alltherapeuticareas.

Products, services and/or techno-logies CINFA’sworkisfocusedonthreeproductran-ges:genericmedicinesinalltherapeuticareas;OTCmedicinesthatdonotrequireprescriptionandwhich includea full rangeoforthopaedicproducts;andanewdermo-cosmeticproductlineunder theBe+brand,with treatments forthecareofallskintypes.CINFA‘scommitmenttoR&Dcanbeseeninitsteamof45professionals,itsdevelopmentcon-tractswith37universities,nationalandforeignresearchcenters,andtheEUR49.8millionin-vestment in the last fiveyears.This figurewillrisetomorethanEUR77millionbetween2010and2014.AmongstCINFA’sR&Dprojects,thecompany continues to focus on the develop-

mentofpotentdrugs,especially fortheareasofoncologyandtransplant.Thelaboratoryhasplanstodevelopfourteengenericdrugsofthisnatureby2011.

Main infrastructuresCINFAhastwo industrialplants for themanu-facture of its own products, both located inNavarra. The first has an area of 17,000 m2and manufactures most of CINFA’s produc-tion.Thesecondwasconstructedonaplotof48,000m2anditconsistsofabuildingforthestorage,managementanddispatchoforders,a laboratoryequippedwithcutting-edgetech-nologyandanoral-solidsmanufacturingplanttoproducehighlypotencygenericdrugs.

Achievements and future prospectsApart from being the leading Spanish phar-maceuticalcompanyintermsofthevolumeofsalesthroughretailpharmacies,CINFAisalea-dingcompanyinitsseveralbusinessstrategies.

Regarding the generic drug market, CINFAis the leading Spanish company with a23.27% market share. Currently, one in fourgeneric drugs in Spanish homes are sold byCINFAandthecompanyhassoldover275mi-llionunitssince1998.CINFA is ranked second among the SpanishpharmaceuticalcompaniesintheOTCsector.In the Orthopedics market, the Farmalasticbrandistheleaderinpharmacieswithamarketshareexceeding40%.Allinall,CINFAkeepsonresearchingandfocu-singonnewbusinesslinestomeettheneedsofsocietyindifferentareasofhealthcare.

TravesíadeRoncesvallesnº1PolígonodeOlloki,31699(Navarra)T(+34)[email protected]

contact PersonJulioMaset(DirectorofInnovation)

laboratorios cINFA s.A.Therapeutics >

16 companies // Product development companiescompanies // Product development companies

general descriptionThe biotechnology company “Digna Biotech”wascreatedasaspin-off from theCenter forAppliedMedicalResearch(CIMA)oftheUniver-sityofNavarrainPamplona.Dignahasateamof28employeesandwhosegoalistodeveloptheresearchproductsgeneratedatCIMA.WiththecollaborationofCenterforAppliedPharma-cobiologyResearch (CIFA), different Facultiesof the University of Navarra, the UniversityClinicofNavarra (CUN),aswellasCIMA, thecompanyleadsthepreclinicalandclinicaltrialsof the new therapeutic approaches devised,anditperformsthedocumentationofexistingproducts.ThefinalobjectiveofDignaBiotechistoaddvaluetotheproductsinordertoob-tain license agreements with pharmaceuticalcompanies tocomplete theirdevelopmentsothattheymayreachthemarket.Fromitscon-ception,thecompanyownsanextensiveseriesofproductsand technologies thathavebeenlicensedbyCIMA.ThemodelofDignaBiotechisapioneeringinitiativeinSpain,althoughitisverysimilartoothermodelsdevelopedindiffe-rentNorthAmericanuniversities.AmongthemostimportantSpanishfirmsfromtheindustrialandfinancialsectorthatinvestinDignaBiotechare:SODENA,Ungríapatentesymarcas,CajaNavarra,BBVA…

Priority areas Oncology, Neurosciences, Hepatology, Car-diovascular diseases, Dermatology, Ophthal-mology

Products, services and/or techno-logies The company owns 33 patents, aswell as apipeline of 47 products and biomedical re-searchapplications indevelopment:38 in thetherapeuticareaand9diagnosticproducts.

Therapeutic development products:PhaseIII:P144-Dermatology(Sclerodermia, >skincancer,actinickeratosis)PhaseII:IFN-Hepatology(HepatitisC) >Phase I:CT-1 -Hepatology (Transplantand >Resection)Preclinical: >

P17-OncologyandOphthalmology (He->patocarcinoma,Bonemetastasis,Macu-lardegeneration).EDA - Infectious and oncological disea->ses.

MTA-Immunology(Multiplesclerosis)>4PBA-Neurology(Alzheimer).>VectorAAV-Hepathology(Porphyria).>

Diagnostic products:Clinical validation: URIFIB - Hepatology (Fi- >berurinarymarker).Preliminaryvalidation: >

Osteosarcomamarkers - Oncology (Os->teosarcoma).DNAmutationdetectiontest.>APO-A1-Oncology(Hepatocellularcarci->noma).

R&D: >MTA Prognostic treatment markers for>Multiplesclerosis.MetabolomicprognosticmarkersforMul->tiplesclerosis.

Achievements and future prospectsAt presentDigna has licenced2 compoundsandithas3productsthathavereceivedactiveinvestment and that are under development,all inclinicalstage.Therearealso9productsin the initialphaseofdevelopmentand4pro-ductswithprivateexternalfinancing.Digna has reached agreements with compa-niesbothinSpain(Isdin)andabroad(Biotech-nol,AMT,Genentech),aswellascreatingnewcompanieswith the new intellectual propertygenerated.Since its foundation, the solid projects thathavebeenestablishedbyDignahave reinfor-ced the investors’ confidence (including thatoftheregionalgovernmentinNavarraandtheSpanishgovernment),whichhashelpedDignatoobtaintheprivateandpublicfundingneces-saryforittogrowsteadilyovertheyears.The company plans to increase the numberofproductsreachingtheclinicalstagesofde-velopment, searching for early licencing andexternal investors for some of their projects,both through the internal development of theproductsorthecreationofnewcompanies.

Avda.PioXII22,Oficina231008Pamplona(Navarra)T(+34)[email protected]

contact PersonPabloOrtiz(CEO)

Digna Biotech s.l.TherapeuticsandDiagnostics >

Product development



companies // Product development companiescompanies // Product development companies

general descriptionOjer Pharma is a spin-off company from theUniversity of Navarra that tightly collaborateswith thisUniversity’sCenter forAppliedPhar-macobiologyResearch(CIFA).Thecompanyisfocusedonthedevelopmentoftherapeuticder-matologicalproducts.Theoriginalityofitsworklies increatinginnovativeassociationsofexis-tingactive ingredients,and thenapproachingthe skin condition from an equally innovativeangle. Their products seek to simultaneouslytreattheetiological(causes)andsymptomato-logical (associatedsymptoms)aspectsof theillness.Thecompanyworkstoidentifyexistingtreatment ‘niches’ togeneratedermatologicalsolutionsthatcoverpatients’needs.ThemainbackersofthecompanyaretheUni-versityofNavarraFoundation(FUNA),theCEOof the company (Carlos González Ojer), twoventurecapitalfunds(RondaVidaandRealdeVellón)andSODENA.

Priority areas Dermatology

Products, services and/or techno-logies Ojer Pharma’s product portfolio consists ofaround10 incremental innovationproducts intheareaofdermatology.ThemostdevelopedproductsarefocusedonAntisepsisandDesin-fection,Anti-ulcer,Anti-acne,Hygieneandskinprotection:

Previdersin©, Ojer Pharma’s first product, >has successfully completed preclinical andclinicalstages,anditspatenthasbeenfiled.TheproductinformationhasbeensubmittedtotheCompetentAuthorityforevaluation.IncollaborationwiththeUniversityofNavarra >and theUniversityofBarcelona,OjerPhar-mahasdevelopedaninnovativetechnology(Bioadhesive Lipogels and Hydrogels) thatwill leadtomoreefficientandsaferdeliverysystemsforthetreatmentofdermatologicaldiseases.Thistechnologyhasbeenappliedsuccess- >fully to Nobactine®, the company’s secondproduct,whichhassuccessfullycompletedpreclinicaldevelopmentandforwhichapat-ent has been filed. In the comingmonths,OjerPharmawillinitiatetheclinicaldevelop-mentoftheproduct.

Main infrastructuresOjerPharmahasincorporatedabusinessma-nagementtoolthataroseasaresultofthetho-rough investigation of current organizationalmodels of R&D. The R&D Management Unit(referredtoas“UGIDI”accordingtoitsSpanishabbreviation)isanunparalleledsystemtoma-nageresearch,developmentandimplementa-tionactivities, incompliancewithanumberofrules (UNE 16600X) that conform with Euro-peanregulationstoguaranteeboththequalityandsuccessofR&Dactivities.

Achievements and future prospectsOjerPharmarecentlyobtainedtheEIBTBrand(TechnologyBasedBusiness)throughtheNa-tional Association of Spanish BICs (ANCES).OjerPharmahasalsobeenawardedSMEsta-tusbytheEuropeanMedicinesAgency.

Etxesakan28,“AzysaBuilding”Groundfloor,office331180ZizurMayor(Navarra)T(+34)[email protected]

contact PersonCarlosGonzálezOjer(CEO)

Ojer Pharma s.l.Therapeutics >

Product development

18 companies // Product development companies

general descriptionProRetinaisaspin-offfromtheCenterforBio-logicalResearch(CIB-CSIC)thatisdevelopingtheresults inneuroprotectionobtainedbytheLaboratoryofDevelopment,CellDifferentiationand Degeneration at this intitution. The com-panyhas9employeesanddevelopsdrugsforthe treatment of ophthalmological diseases,specifically retinal dystrophies and degenera-tions.Themain investors of the company are CajaNavarra,ClaveMayor,Inveready,Sodenaandthefoundingpartners.

Priority areas Ophthalmology

Products, services and/or techno-logies One of their target projects is the preclinicalandclinicaldevelopmentofaneuroprotectivefactorforthetreatmentofretinitispigmentosa.Thecompanyisalsoworkingonagenethera-pyapproachtotreatretinitispigmentosa.InDecember2008, theFDAand theCommi-tteeforOrphanMedicinalProductsoftheEMAadopted the designation of Orphan Drug forProretina´sneuroprotectivefactor.

Achievements and future prospectsProRetinahastakenaproductfromacademiato the preclinical stage of development in averyshorttime,completingthemanufacturingoftheactiveingredientandformulationinlessthanoneyear.Thecompanyhasalsoobtainedorphan drug designation and secured patentprotectionforitsleadingproduct.

PlazaCEIN5.DespachoT531110Noáin(Navarra)T(+34)[email protected]

contact PersonStuartMedina(CEO)

Proretina Therapeutics s.l.Therapeutics >

Product development



general description3P Biopharmaceuticals is a CMO (ContractManufacturing Organization) that developsandproducesrecombinantproteinsforthera-peuticanddiagnosticuse, aswell as fornontherapeutic use, and that designs and deve-lopsprocessesandproductstobeusedincelltherapy. 3P accompanies its clients from theinitial R&D stages, through the proof of con-cept, and the preclinical and clinical trials, tothecommercializationoftheirproducts.With 32 employees, 3P is a biotechnologicalcompanywith the capacity and resources toproduce recombinant proteins of the higheststandardandquality,suchasthatdemandedbytheEMAforthirdpartyuse.3P aims to become a leading CMO in theEuropean biotechnology sector, capable ofsuccessfully participating in the developmentof projects and in manufacturing processeswithinkey internationalmarkets, therebycon-tributingtotheenhancedhealthandwell-beingofoursociety.3PBiopharmaceuticalshasthesupportofkeyregionalgovernmentagencies,financialinstitu-tions, and pharmaceutical and biotechnologi-calcompanies.

Priority areas 3P´stargetclientsareBiopharmaceuticalandBiotech companies actively developing bio-pharmaceuticals and/or diagnostic proce-dures, Multinationals requiring additional andflexible processing capacity with a qualitysystemcomparabletotheirown“QualityStan-dards”, Research Centers and internationalcompaniesfromcountriesoutsidetheEUthatrequireofficialapprovalfortheirproductsfromtheEMAinEuropeandtheFDAintheUSA.

Products, services and/or techno-logies 3P Biopharmaceuticals offers the followingproductstoitsclients:Recombinantproteinsfortherapeuticanddi- >agnosticuse(forhumanandanimalhealth):Monoclonal antibodies, Vaccines, Biosimi-lars.Proteins for non-therapeutic use (food, >estheticsandindustrialuse).Developmentandmanufactureofproducts >foradvancedtherapies:

Cell therapy and tissue engineering pro->ducts.Intermediate products: GMP cell culture>media, biomaterials (scaffold or matri-ces).

3PBiopharmaceuticalsoffersthefollowingser-vicestoitsclients:Expressionsystems. >Fermentationofbacteria,fungus,andyeast >upto1,000L.Productionfrommammaliancellsupto400 >L(disposable).Proteinpurificationfromprokaryoticandeu- >karyoticsystems.Generation and characterization of cell >banks(MCBandWCB)forprokaryotes/eu-karyotes.AnalyticalDevelopment. >CultureandmaintenanceofcellsunderGMP >conditions.StabilityAssays. >

Main infrastructuresAproductionplantof4,600m®wheretheca- >pacityfordevelopmentandproductioncanbeincreasedaccordingtotheneedsoftheclientand/orthemarket.EquipmentandprocessesadaptedtoGMP >specifications.Proteinpurificationfromprokaryotic/eukaryotic >systems. Fermentation of bacteria, fungus,andyeastupto1,000L,andproductionfrommammaliancellsupto400L(disposable).

Achievements and future prospectsDuetoitsnewproductioncapacity,over2,000liters,anditsnew“FillandFinishing”line,3Pwillincreaseitsproductioncapacitytoproduceupto commercial phases, aswell as to developandproducebiosimilarproducts.

PolígonoMocholí.C/Mocholí231110Noáin(Navarra)T(+34)[email protected]

contact PersonDámasoMolero(CEO)

3P Biopharmaceuticals s.l.ContractManufacturingOrganization-CMO >

support services

companies // support service companies

20 companies // support service companies

general descriptionActivery isanamorphizationandparticlepro-ductioncompanythatdevelopsandproducesnewamorphousdosageforms,andinnovativemicroandnanoparticles.FoundedbyCarlesVentosaandAndreasKor-dikowski, Activery operateswith the financialsupportofprivate investorsandventurecapi-tal organizations, such as Sodena andClaveMayor. The company hasplans todouble itscurrentstaff(5people)inthenearfuture.

Priority areas The core strategy of Activery is to create astrong patent portfolio based on processes(technologies)andproducts(proofofconcept).Throughamorphizationand/orparticledesignstrategies,Activerycanquicklycreatewelldi-fferentiateddrugproductsfromexistingAPI´s.Ourultimategoal is tocreatenewmedicines,eitherthroughpartneringprogramswithphar-maceutical companiesor fromourownpipe-line.

Products, services and/or techno-logies Activery has developed a new proprietaryprocess:ASP (AtmosphericSupercriticalPre-cipitation).Thistechnologyiscapableofprodu-cingamorphousandcrystallineparticles(micro&nanoparticles)inordertoobtainourprincipleproducts:Early generics - Activery develops stable >amorphousformstopermitearlygenericen-tryonthedateofpatentexpiry.New combinations - Amorphous combina- >tions of active ingerdients to create stableamorphous molecular dispersions with im-proved solubility and distinct pharmacoki-netics.New prodrugs and derivatives - Improving >safetyandeficacitythroughminormodifica-tionsofexistingAPI´s(exploratoryprojects).

Thecompanyalsooffersthefollowingservices:ConsultancyregardingAmorphization. >Thermal analysis service for solid-state de- >termination(DSC&TGA).

Achievements and future prospectsAt present, Activery owns 5 international pa-tents: 3 for new products and 2 patents onscalable micro and nanoparticle productionsystems.Activery aims to become a key player in thepharmaceuticalmarket,whilemaintaining se-veral co-development programs with interna-tional pharmaceutical companies. In the nearfuture,Activerywill have its owncGMPcom-pliant facilities inNavarra in order toproducepowderssuitableforhumanclinicaltrials.

AvdaCarlosIII,36.1ºDerecha31003Pamplona(Navarra)T(+34)[email protected]

contact PersonCarlesVentosa(CEO)

Activery Biotech s.l.Productdevelopmentanddrugdeliverytechnologies >

Product development

support services




general descriptionBionanoplus is a company that specializes inthe research and development, productionandmarketingofpolymericmicroparticlesandnanoparticlesfordrugdelivery,vaccinationandimmunotherapy.Bionanoplus is owned by the entrepreneurDr. Hesham Salman and two venture capitalfunds:StartUpCapitalNavarraandInvereadySeedCapital.

Priority areas Pharmacy (Anti-cancer immunotherapy),vete-rinary(Microbialinfection),cosmetics,personalcare,food,beverageandagriculture.

Products, services and/or techno-logies Bionanoplus offers the following innovativeproducts: Bioadhesive MicroH, NanoG andNanoCAPH for buccal, dermal, ocular, nasalandvaginaldrugdelivery.BionanoplusalsooffersSNAPFORMULA,theinsitufabricationofproteinnanoparticlesforIVandSCdelivery.

Moreover, the company offers the followingservices:A consultancy service for thedevelopment >of nano andmicroparticulate drug deliverysystems, including initial formulationdesignandadjustmentofknow-how.The development, industrial design and >evaluation of microparticles and nanopar-ticlesforthedeliveryofchemicaldrugs,bio-active molecules (Proteins, peptides, etc.),vaccinationandimmunotherapy.

Achievements and future prospectsOurmission is to create aprofessional struc-ture,aimedatmakingscientificandinnovativediscoveries into themost relevant aspects ofnanotechnologyanditspotentialapplications.

Pol.Mocholí,PlazaCEIN5.NaveB1431110Noáin(Navarra)[email protected]

contact PersonHeshamSalman(DirectorR&D)

Bionanoplus s.l. Drugdeliverytechnologies >

support services

22 companies // support service companiescompanies // support service companies

general descriptionCibNavarra is a consultancy agency speciali-zed inpharmaceuticalR&Dandother health-carerelatedproducts.CibNavarra is a personal iniciative of IdoyaCalvo,CEOandSeniorConsultantofthecom-pany,fromher20yearsexperienceasprofes-sor anddirector of thequality assuranceunitin theUniversityofNavarra,andasanexpertoftheEMA.CibNavarrahas4employeesandcollaboratesin theevaluationof themost recentproductsapprovedbytheEMA.

Priority areas Thecompanyhastwofocusareas:Optimization of resources for Biotech and >non-Biotechproductsandprocessesrequi-ringspecialdevelopment.Development of integrated management >systems combining different systems tomanage Quality Control that are appliedon a case by case basis, according to theUNE166000standard (R&Dand innovationmanagement).

CibNavarra´s target clients are biopharma-ceutical companies with R&D activity relatedtodrugdevelopmentand thatofotherhealthproducts (cosmetics, medical devices, novelfoods, etc…). Their customers include:DignaBiotech, 3P Biopharmaceuticals, ProgenikaandLactest,amongothers.

Products, services and/or techno-logies Thecompany’smainservicesarefocusedonstrategicprojectdevelopmentandregistrationofnewproducts,qualityassessment,training,incorporation of new technologies in projectmanagement, vendor evaluation, evaluationof records,evaluationof theCTDofnewpro-ductsandpre-officialaudits.CibNavarracarriesout itsownR&Dactivity inrelation to the development of managementsystems supported by ICT applications anditsobjectiveistoachieveaninformaticstooltooptimizemanagementresourcesthroughspe-cific indicators,prioritizingprojectsandtakingappropriatedecisionsbasedonobjectivedatafromtheorganizationunderstudy.

Achievements and future prospectsCibNavarraaimstobecomethereferencesu-ppliertodefineregulatorystrategyandqualitycontrolforbiopharmaceuticalR&D,aswellasprovidinganintegratedsoftwareapplicationtomanageR&D formedicines and other healthproducts, with specific indicators that serveto rank projects and prioritize business deci-sions.

Etxesakan28.EdificioAzysa.Oficina2.31180ZizurMayor(Navarra)T(+34)[email protected]

contact PersonIdoyaCalvo(CEOandSeniorConsultant)

cibNavarra-consultora de Investigaciones Biomédicas de NavarraQualitycontrolandregulatoryconsultancy >

support services



companies // support service companiescompanies // support service companies

general descriptionGeiser Pharma offers its worldwide partnersthepossibilitytocarryoutPharmaceuticalde-velopmentactivitiesfromtheinitialselectionofalternatives to the final registration, includingthe licensing and supply of the final product(Pharmaceutical Development, Clinical Stu-dies,RegulatoryandLicensing).Themaingoalistofocusitsportfolioandservicesonselectedproductsthathaveadditionalvalueandinvolvethe application of advanced technologies, in-cludingnicheproducts.Geiserpharma uses its know-how and expe-rience in the selection and design of theseproducts. Geiserpharma complements R&Dactivitieswithawellexperiencedteaminbusi-nessdevelopmentandcomercialstrategiesinregulatedmarkets.

Priority areas Nonstandardpharmaceuticaldosageforms.

Products, services and/or techno-logies Thecompanyoffersthefollowingservices:Business Intelligence -market analysisand >opportunityselection.PharmaceuticalDevelopment-DMFevaluation, >IPanalysisandlegalstrategies,APIanalysis,Pre-formulation and formulation, Scale-upand Implementation, Pilot Batches, Manu-facturing Process Validation, Stability stu-dies,Expertreport.Clinical studies - CRO selection, Clinical >study protocol, Clinical Experts report, Bi-bliography.Regulatoryaffairs-Regulatoryaffairsstrate- >gies, Dossier compilation and submission,Regulatorysupport.BusinessDevelopment:Customerselection, >Commercialagreements inEU,NetworkingforCommercialactivities.

Thecompanyalsooffersawiderangeofnon-standarddifferentdosageformssuchas:Microeffervescent technology direct to >mouth.Hardlozenges. >Liquidsandtablets. >Injectables. >Oraldispersabletechnologies. >Effervescents. >Softgelcapsules. >

Liophilized. >Semisolids. >

Achievements and future prospectsCurrently the company is running up to 30added valued and niche projects for its twobusinesslines,contractresearchandoutlicen-sing. Geiserpharma focuses both these linesontheEuropeanMarket,butinthenearfutureitplanstoentertheUS,anditisevaluatingnewbusinesslinestobeimplementedbythecom-panyinthenearfuture.

AvenidaBajaNavarra1,4ºE31002Pamplona(Navarra)T(+34)[email protected]

contact PersonCarlosYañez(ScientificDirector)DavidZubeldía(BusinessDevelop-mentManager)

geiserPharma s.l.PharmaceuticalDevelopment >

Product development

support services

24 companies // support service companies

general descriptionIDIFARMA is a reference company offeringR&Dservices topharmaceuticalandbiotech-nologicalcompaniesacrossEurope.Thankstothewiderangeofservices,itshigh-performan-ceequipmentandstrictquality-controlsystem,thecompanycanofferefficientsolutionswithinsuitabledeadlines.IDIFARMAhasastaffof60anditoffersa“onestopshop”servicebyhandlingtheallaspectsoftheprojects,formulatinganddesigningdrugmanufacturingprocesses,developingandvali-datinganalyticalmethods,andmanufacturingand supplying the products required for theclinicaldevelopmentofnewdrugs.IDIFARMAisanauthorizedpharmaceutical la-boratoryandishasbeencertifiedascomplyingwithGoodManufacturingPractices(GMP)andGoodLaboratoryPractices(GLP).The entrepreuners behind IDIFARMA are:Angel Ursúa, Luis Oquiñena and José JavierMuruzábal,alloriginallyfromthepharmaceuti-cal industry. Other investors are: SODENA,Clave Mayor, Caja Rural, Corporación CAN,FundaciónUniversitariadeNavarra(FUNA).IDIFARMA has full understanding and expe-rience in the regulatory frameworkrelevant tothedevelopment of newdrugs and it appliessuitablestrategiesofpharmaceuticaldevelop-mentwithinthatframework.

Priority areas IDIFARMAhasexpertiseinthedevelopmentofhighly active products. The GMP productionplant for clinical trial batches is dedicated tothe manufacturing of cytotoxics, cytostatics,hormonalsandhormonalinhibitorsinsoliddo-sageforms,andtheirplacebos.IDIFARMAworksinallexperimental,documen-taryandadvisory tasks that anewdrugmayrequiretogainmarketingauthorisation.

Products, services and/or techno-logies IDIFARMAoffersawiderangeofPharmaceuti-cal Development and CustomManufacturingServices: formulation and analytical develop-ment,stabilitystudies,clinicaltrialmanufactu-ring(includinghighpotencyproducts),clinicaltrialsupply(packagingandlabeling),regulatory

support, technology transfer, optimization ofmanufacturing processes, general manage-mentofbiopharmaprojects.Alltheseservicesareaimedatofferingthefas-testandthemosteffectivewaytolaunchyourproductintothemarket.

Main infrastructuresIDIFARMA´smaininfrastructuresarethecGMPmanufacturingPlant forPilotandClinicalTrialbatches,ahighcontainmentareaof980m®forthe manufacturing of cytotoxics, cytostatics,hormonals and hormonals inhibitors in soliddosage form. It also counts on an AnalyticalDevelopmentandQualityControlLaboratory,a Galenic Development Laboratory and theStabilityStudiesArea.

Achievements and future prospectsIDIFARMA specializes in the development ofcomplicated products, such as: high activityproduct development (oncologicals and hor-monals), sustained release product develop-ment(pHdependentandpHindependent),de-velopmentofinnovativepharmaceuticalforms(transdermalpatches,microtablets,liposomesandnanoparticles)andformulationscontainingpeptides.The internationalizationof thecompany is thechallengeforthefollowingmonths.IDIFARMAisawell establishedcompany in theSpanishmarketanditisnowenteringtheGerman,UKandFrenchmarkets.Severalagreementswithmediumsizecompa-nieshavealreadybeensignedfortheoutsour-cingofservices:“onestopshop”projects,qua-litycontrolandbatchreleaseissuesandpartialdevelopment.

PolígonoMocholí,c/Noáin131110Noáin(Navarra)T(+34)[email protected]

contact PersonLuisOquiñena(CEO)

IDIFArMA, Investigación, Desarrollo e Innovación farmacéutica s.l.PharmaceuticalContractDevelopmentOrganization >

support services




general descriptionPharmamodellingS.L.isaconsultingcompanyspecializedindataanalysisandpharmacokine-tic/pharmacodynamic modeling for the phar-maceutical and biotechnology industries, aswellashospitalsandpharmaceuticalresearchdepartments.ThecompanyisownedbyanentrepeneurandaGovernmentofNavarraFund(FondoJoven).PharmamodellingS.L.offersstrongknow-howto optimize the development of drugs usingpharmaco-statistical models that summarizepharmacokineticandpharmacodynamicinfor-mationfromthedifferentphasesofdrugdeve-lopment.

Priority areas Pharmacokinetic and pharmacodynamic mo-dels, drug/disease models, interactions be-tweendrugs,especially focusedontheareasofmultitherapy,individualizeddosageregimes,toxicokinetic/pharmacokineticanalysis.

Products, services and/or techno-logies ThemainservicesofferedbyPharmamodellingare:Elaboration of pharmacokinetic and phar- >macodynamicmodels.Elaborationofdrug/diseasemodels. >Studyof interactionsbetweendrugs,espe- >ciallyrelevantintheareaofmultitherapy.Designofindividualizeddosageregimes. >Mechanisticbiomarkermodeling. >Theapplicationofmodelingandsimulations >tokeydevelopmentdecisions.Statisticalanalysis. >BioequivalenceandToxicokineticstudies. >

Although Pharmacokinetic/pharmacodynamic(PK/PD) modeling is not a new science, inrecent years it has advanced significantlythrough the development of Monte-Carlobased simulation programs that can beused to design and simulate clinical trials.

This approach is a powerful extension ofclassical PK/PD modeling as it integrates anestablished PK/PD model with estimates ofvariability.

These advances enable drug exposure anddrug response to be predicted in the targetpatient population, together with an estima-te of the associated variability. Perhaps thetruestrengthof thisapproach is theability torun “what-if” scenarios on previously untes-teddosing regimes inorder topredictclinicaloutcomes.Thisability toperform“virtualclini-caltesting”ofanewdrugoftengivesvaluableinsightintooptimaltrialdesignforfutureclinicaltesting.Thistoolassistsinvestigatorstomakebetterdevelopmentdecisionsthrougharatio-nalandintegratedanalysisofallthedataavaila-blewhenadvancingwithanewproject.

Achievements and future prospectsIn2006,thePharmamodellingprojectreceivedanEIBTawardfromtheGovermentofNavarrainrecognitionofitsroleasaTechnologyBasedInnovative Enterprise.Moreover, thePharma-modelling projectwon a “BestBusiness ideafromPhD”Ideactivaawardin2007.Pharmamodelling S.L. began its activities in2010 and it is currently a strategic partner ofDynakinS.L.

Pol.Mocholí,PlazaCEIN1-5NaveT331110Noáin(Navarra)T(+34)948346615(+34)[email protected]

contact PersonOnintzaSayar(CEO)

Pharmamodelling s.l.Drugdiscovery >

support services

26 universities and research centersuniversities and research centers

general descriptionTheBiomedicalResearchCenter(CIB)isapu-blicR&DinitiativepromotedbytheGovermentof Navarra, Health Department. The Center(some11,000m2) is currently under construc-tion inthesurroundingsoftheHospitalofNa-varraComplexbutitwillbefini-shedbytheendof2011.TheCIBwill be the fundamental pillar for thedevelopment of the R&D Health DepartmentStrategic Plan (2008-2011) that establishedpriorityR&DlinesforNavarra’sHealthService.Amongthemostoutstandingareasofactivityare:Oncology,Neurosciences-Psichiatry,Car-diovascularSciencesandCellTherapy.TheCIBwillcarryoutbiomedicalR&Dactivityaswellasofferingseveraltechnologyplatformsand support units to provide these technolo-giestoresearchersintheregionalHealthServi-ceinacentralizedandefficientway.Inthiswaythe center will contribute to the translationalresearch in the region and it will help increa-sethequalityofresults.Inaddition,itwillhelpmeet the technological needs of the sector,complementing theexisting technologiesandcontributing to theeconomicdevelopmentofNavarrabyboostingbiomedicalR&Dactivity.TheMiguelServetFoundation,aprivatefoun-dationestablishedby theGovernmentofNa-varra, will coordinate and manage the CIB,guaranteeingagilityandefficiencyineverystepoftheresearchprocess.

Priority areas Thetargetdiseasesthat theCenterwill focuson are Oncology, Neurosciences-Psychiatry,CardiovasculardiseasesandCellTherapy.The center has special strength in Genetics,Bioengineering, Biomaterials and Nanomedi-cine,Telemedicine,PharmaceuticalResearch,Epidemiology,PublicHealthandHealthservi-ces,Primaryhealthattention.

Achievements and future prospectsTheCIB´saim is todevelopan innovative re-search model in line with other internationalcutting-edge initiatives, boosting the biome-dical research carried out within the NavarraHealthServiceatan international level,and inclosecooperationwith theprivatesectorandotherbiotechnologycenters.The CIB will support the “setting up” of bio-technologicalenterpriseswithcommonsharedand complementary objetives to the currentR&DCIBlines.

C/Irunlarrea3HospitalofNavarraComplex31008Pamplona(Navarra)T(+34)[email protected]

contact PersonKatyPérezEquiza(CEO)

centro de Investigación Biomédica (cIB)

research center



universities and research centersuniversities and research centers

general descriptionTheUniversityofNavarra,throughtheFounda-tion forAppliedMedicalResearch (FIMA),setup the Center for Applied Medical Research(CIMA)in2004.ThisCenteristheresultoffiftyyears’R&DexperienceattheSchoolofMedici-neandtheUniversityClinicofNavarra,aswellastheSchoolsofSciencesandPharmacyandtheCenterforAppliedPharmacobiologicalRe-search (CIFA). It alsomaintains a relationshipwiththeSchoolsofEngineeringandNursing.TheCenteriscomposedofaround400resear-chers from 25 European, African, AmericanandAsiancountries,whoworkincooperationwithotherinternationalcenters,publishingover100articleseachyearinspecialistjournals.CIMAbringspureresearchclosertoitsclinicalapplication, and it collaborateswith thephar-maceutical and biotechnological industry todevelopproductsfordiagnosisandtreatment.The interdisciplinarywork carriedoutbyphy-sicians, biologists, biochemists, pharmacists,engineers, laboratory technicians and otherprofessionals isorganized into fourpriority re-searchdivisions:GeneTherapyandHepatolo-gy, Cardiovascular Sciences, NeurosciencesandOncology.Initially, CIMA is financed through a researchandtechnologytransfercontractwith15Spa-nishinstitutionsandcorporations.Researchersalsoreceivegrantsandothertypesoffundingfor specificprojects. In themid- to long-term,theaim is tobeself-financing throughthepa-tentsthatresultfromitsresearchwork.CIMA participates in all the competitive re-search programs on a regional, national andinternational level. It is recognized by theMi-nistry of Education and Science as a Centerof Innovation and Technology, and it formedpartofoneof thegroups in thefirstprogramofStrategicNationalConsortiumsinTechnicalResearch(CENIT).DignaBiotechisaspin-offcompanythatemer-ged fromCIMA.Digna’s objective is to carryoutclinicaltrialsandbringtothemarketdiag-nostic and therapeutic products discoveredandpatentedbyresearchersatCIMA.

Priority areas GeneTherapyandHepatology,CardiovascularSciences,NeurosciencesandOncology.

Products, services and/or techno-logies

gene Therapy and Hepatology Division: >Devoted to study the mechanisms under-lying liver diseases, and to develop newtherapeutic and diagnostic strategies. Themain focus of the research is on chronichepatitis,livercirrhosis,biliarydisordersandlivercancer.Specialattention ispaidtotheapplication of gene therapy tools to treatliverdisorders, includinghepatocellularcar-cinoma, viral hepatitis, metabolic diseasesandlivercirrhosis.cardiovascular sciences Division: > Re-search in this area focuses on identifyingsubstancespresentinthebloodthatcanaidtheearlydiagnosisofpeopleatriskofheartfailureandmyocardial infarction,aswellasstrokes,sothattheycanbetreated intimetopreventcomplications.Neurosciences Division: > This divison isfocused on the genetic and molecular ba-sis of neuronal death in Alzheimer’s andParkinson´s disease, including the cellularmechanisms involved in the origin of me-moryloss.Oncology Division: > lung cancer is one ofthemainfieldsofresearch,theaimofwhichistofindouthowtumorsdevelop,fromtheirveryfirstmomentuntiltheybecomecapableofinvadingotherorgans.Intermsifhemato-oncological research, the aim is to explorenewtreatmentstocorrectgeneticdisordersinleukaemiaandlymphoma,andtoproducevaccines against lymphoma that can beusedinclinicaltrialsonpatients.

Achievements and future prospectsCIMAisexperiencedinFrameworkProgramme(FP),withtwoFP5projects,6FP6projects,2MarieCurieGrants,and9projectsinFP7(7co-llaborativeprojects,onecoordinatedbyFIMA,oneMarieCurieGrantandoneERANET).Since2004FIMAhashandled40patentsfromthe fourmain R&D areas, 33 of which camefrom the Gene Therapy and Haematologyarea.Inaddition,CIMAresearchershavenowcollaborated inmore than20Clinical Trials intheUniversityClinicofNavarraassociatedwiththescientificissuesdealtwithintheCenter.

Avda/PíoXII,5531008Pamplona(Navarra)T(+34)[email protected]

contact PersonJesúsHernández(COO)

centro de Investigación Médica Aplicada (cIMA)

research center

28 universities and research centers

general descriptionTheNationalMedicalImagingCenterinNava-rra isapublicR&D iniciativepromotedby theGovernment of Navarra Health Department.TheCenter’smainmissionistobecomeanin-ternationalandnationalCenterofExcellence,providing services and carrying out scientificresearchinthefieldofMedicalImaging.Itaimsto serve the national scientific, technologicalandbusinesscommunity,aswellascollabora-tingataninternationallevel,allowingallinteres-tedgroupsaccessto its installations, therebygenerating results that could potentially betransferredtoindustry.Itisestimatedthatthecenterwillemployacorestaffofabout15people,withbetween20and30doctoralandpostdoctoralfellows.The administrative and financial board of theNational Medical Imaging Center will be amixedConsortiumorFoundationcreatedwiththe participation of theRegionalGovernmentofNavarraandtheNationalMinistryofScienceandInnovation.

Priority areas This new Center will carry out research andprovide services tomultidisciplinary researchgroups,pharmaceuticalcompanies,manufac-turersofMedicalImagingequipmentandhos-pitals, focusingonall threestagesofMedicalImaging: data acquisition, data processing,andimageinterpretationtoreachadiagnosis.

Products, services and/or techno-logies TheCenterwillbeequippedwiththelatesttechnologies available internationally for re-search use, both for external users, as wellasforthepersonelresidentatthecenter.TheCenterwillservethreefunctions:It will make available its highy specialized >services, infrastructure and equipment toresearchprofessionals.As a Research Center, it will develop its >ownR&Dactivities,aswellasofferingR&Dservices and collaborating in joint researchprojects.It will become a Reference Center for the >normalizationandaccreditationofprocess-ingtoolsforMedicalImagingwherebycom-paniesinthesectorcouldvalidatetheirnewapplications.

Regarding itsareasof activity, theCenterwillcarryoutresearch intheareaofdataacquisi-tionanditwillassistinthedevelopmentandim-provementofMedicalImagingtechnologies.Intheareaofdataprocessing,itwillworkactivelytowards improving the filtering, registration,segmentation and fusion of medical images,whileitwillalsodeveloptoolstohelpintheareaofinterpretationanddiagnosis.

Achievements and future prospectsTheCenter’smainmissionistobecomeanin-ternationalandnationalCenterofExcellence,providing services and carrying out scientificresearchinthefieldofMedicalImaging.The Center will have a Scientific AdvisoryBoardofrenownedprestige,madeupofdirec-torsandresearchers fromthemainreferencecentersworldwide inMedical Imaging,whichwill ensure the pioneering nature of theworkandthequalityinthestrategicplanningforthecenter.

CalleAmayaN.º2-A31002Pamplona(Navarra)T(+34)[email protected]

contact PersonLuisM.LarrayaGalarza(DirectoroftheTechnological-MedicalComplexofNavarra-NavarraHealthService)

centro Nacional en Imagen Médica de Navarra

research center



universities and research centers

general descriptionFideNa(FoundationforNanotechnologyR&D)isapublicresearchcentercreatedin2007withthegoaloffosteringtheuseofnanotechnologybytheindustryinNavarra.FideNaisanon-profitmakingFoundationwithSODENA, UPNA and Principia TechnologyGroupasFideNa’smaincontributors.OneofthetargetsofFideNaistodevelopskillsthat canbeused in the transfer of nanotech-nology to industry. Inorder todo this,wearelocatedinthecampusofthePublicUniversityof Navarra (UPNA) and we have establishedourownR&Dlines,someofthemincollabora-tion.FideNacurrentlyhasateamof14people(thatithopestoexpand),withseveralyearsofexperienceinnanotechnologyandtechnologytransfer.Ourmainactivitiesare:Nanofabrication-nanostructuresviainterfe- >rencelithographyincollaborationwithMIT.NanoBio - self-assembly of bio-molecules >(proteins, antibodies) on surfaces or nano-particles for protein purification, geneticmanipulation, drug delivery, sensing andcatalysis.Nanocomposites -cellulose reinforcedwith >nanofibersornanoclays for the food indus-try.Energy–increasingtheefficiencyofPhoto- >voltaic Cells using surface nanostructures,inclucingtheabilitytosimulatethephotoniccrystaleffectusingourownmethodology.Photonics-simulationofphotoniccrystals. >SolGel-fabricationofcoatings,membranes >andadsorbents,paticlesynthesis,xerogels,aerogels….

Priority areas Bio-Nanodevelopments areoneof the areaswhere FideNa intends to become a regionalreference. There are two projects in whichFideNahasalreadystartedtodevelopBiotechskills:

sANBioNs – sABioD: > selfassemblednanodevices. Functionalization of surfaces andnanoparticles with proteins and antibodiesforsensing,catalysis,medical imaginganddrugdelivery.ThisiniciativeisfundedbytheGovernmentofNavarra.MNp Biofilms: > drug delivery for BacteriaBiofilms treatment, includingmagnetic gui-dance, chemical targeting, hyperthermiaand bacterial treatment. Consortium withUniversities (Public&PrivateUniversitiesof

Navarra),TechCenters (Lurederra,FideNa,IdAB)andcompanies (IDIFARMA&3PBio-pharmaceuticals). This iniciative has beenfunded by the Ministry of Science andInnovation-MICINN (ACTEPARC program,GovernmentofSpain)andtheGovernmentofNavarra.

Products, services and/or techno-logies FideNa carries out external R+D projects forpartners, consultancy, training, and internalR+D.

Achievements and future prospectsInjust2yearsofactivity,FideNaisalreadyparti-cipatingintwoprojectsintheareaofbio-nano,bothofwhichhaveachievedenough interesttoraisefundingfromtheRegionalGovernmentofNavarraand/orfromtheSpanishMinistryofScience and Innovation. FideNa is collabora-tingwithsomeofthemajorplayersofNavarrain Biomedicine: Universities, IdAB, IDIFARMAand3PBiopharmaceuticals.FideNaintendstobecomeoneofthereferenceentities inbio-nano inNavarrawithin thenextfiveyears,contributing to thedevelopmentofnicheopportunitiesindrugdelivery,diagnosis,medicalimaging…andalwaysincollaborationwiththerestoftheagentsactiveinthefieldofbiomedicineinNavarra.

CentrodeI+D“JerónimodeAyanz”CampusdeArrosadíac/Tajonars/n31006Pamplona(Navarra)T(+34)[email protected]

contact PersonErnestoBravo(CEO)

FideNa (Fundación I+D en Nanotecnología)

research center

30 universities and research centersuniversities and research centers

general descriptionFoundedinJuly1999,theAgroBiotechnologyInstitute(IdAB)isajointCenterbelongingtothePublicUniversityofNavarra (UPNA), theSpa-nishHigherScientificResearchCouncil(CSIC)andtheGovernmentofNavarra.Withover70employees,themainhealth-rela-tedresearchcarriedoutintheCenterinvolvesthe use of molecular biology to understandrelevantdiseasemechanismsand todeveloptoolsrelatedto:diagnosis,prophylaxis,immu-ne response and biochemical processes ofinfectiousdiseases;thedevelopmentofplantsas biofactories of health-related substances;andplant,microorganisms’andanimalmeta-bolism,physiologyandgeneticswithdifferentimplicationsinhealth.

Priority areas The Center focuses its Agrobiotechnologicaleffortsintwomainlinesofwork:BiotechnologyinAnimalandPlantHealth,andPlantBiotech-nology. Ineachof theseareas thereare3 re-searchgroupsfocusingonMicrobialBiofilms,AnimalHealthandMicrobialBioinsecticidesinthe formerandonCarbohydrateMetabolism,Plants as Biofactories and Agrobiology andPlantPhysiologyinthelattercase.

Products, services and/or techno-logies The Center focuses on Agrobiotechnologicalresearchareasofbiomedical interest throughtheeffortsofthefollowingresearchgroupsac-tiveinhealthrelatedareas:

Microbial biofilms: > The work of this re-search group is centerd on the impact ofbiofilms in the development of chronic in-fections in live tissue (mastitis, otitis, pneu-monia, urinary infections, osteomyelitis)or problems related to medical implants,amongothers.Theresearchfocusesonthemechanismsemployedbybacteria to formand maintain these multicellular communi-ties;theinfluenceofbiofilmlife-formsontheinfectious process associated to bacteriaandresistancetoanti-microbials;theidentifi-cationandcharacterizationofthemolecularandbiochemicalmechanismsinvolvedintheformationofBiofilmsofpathogenicbacteriaand vaccine development against biofilmbacteria.ThemainmicroorganismsstudiedsofarareSalmonellaandStaphylococcus.

Animal-human health: > Theworkofthisre-search group is centerd on applying novelimmunological andmolecular biology tech-niques to understand host-pathogen inter-actions and on to develop vaccines anddiagnostictoolsforlivestockandzoonoticin-fectionscausedbybacteriaandviruses.Im-munologicalissuesareaddressedatthemo-lecular,cellularandindividuallevels.Geneticanalysis isperformedat themicroorganismand host levels. The knowledge generatedon the genetic, biochemical and antigeniccharacterization of the microorganism canbe applied to the fields of pathogenesis,molecularepidemiology,prophylaxisanddi-agnosisofthecorrespondinginfections.ThemainmicroorganismsstudiedsofarareSal-monella, Brucella, Haemophylus, lentivirus(MaediVisna)andmastitispathogens.Plants as biofactories: > The work of thisresearchgroupiscenterdontheproductionof transgenicplants asbiofactories of sub-stancesofbiopharmaceuticalandtherapeu-ticinterest(compoundsandvaccines).Geneexpressioninchloroplastsisthetechnologyused in some of these areas, and specifictransgenicplantsaregeneratedwherenec-essary (generally throughchloroplast trans-formation).DistinctiIsolationandpurificationtechniquesareappliedtoobtainthedifferentsubstancesandnovelvaccines.carbohydrate metabolism: > The work ofthisresearchgroupiscenterdonthestudyofglycogenandstarchmetabolisminplantsandmicroorganisms.Plantsproducinghighlevelsofstarcharebeinggeneratedwithdif-ferentindustrialapplications(biopharmaceu-tical, food, cosmetics,bio fuel, etc.).Noveltechnicalapproachesinmetabolicengineer-ingandmetabolomicsareemployedbythisteam.

Achievements and future prospectsTheresearchcarriedoutandthetechnologicaladvancesachievedat the IdAB lead topubli-cations in internationally recognized journals,patentsofappliedandpracticalinterest,tech-nologytransfertoindustry,studenttrainingonMasters, Technology and Doctoral program-mes,andthedevelopmentofnewenterprises(including spin-offs). The personnel presentlybelonging to theCenterhaveproduced/com-mercialized24patentsinthelast10years(upto2009).

CarreteradeMutilva31192(Navarra)T(+34)[email protected]

contact PersonIñigoLasa(CEO)

Instituto de Agrobiotecnología - IdAB

research center



universities and research centersuniversities and research centers

general descriptionL’Urederra is a non-profit, private Technologi-calCenterthatmainlyappliesitsknowledgeoftechnicalresearchto innovation intheareaofnewmaterials,withspecialemphasisonnano-technology,polymerprocessing,biotechnolo-gyandadvancedenvironments,with theaimof transforming this knowledge into industrialvalue.L’Urederrahas45employeesanditwascrea-tedinJune1999bytheassociationofseveralpublicauthorities,financialorganisations,R&Dorganisations and companies in diverse pro-ductive fields. The organisation is a SpanishCIT (Centerof InnovationandTechnology) re-cognisedbytheSpanishMinistryofScience.In its short lifetime, the center has becomevery active in European research and it hasparticipated inkeyareasofa largenumberofprojects.

Priority areas MaterialstechnologyrelatedtobiomedicineisthemainareaofactivityatL’Urederra,focusingonthefollowingfields:

Production and modification of nano- >particles: This field not only involves themanufacturing of simple and complexnano-oxidesofasmallsizeandhighpurity,butalso thephysical-chemical treatmentofnanoparticles for their subsequent use indispersionsandpolymericmaterials.Thesenanoparticlescanbeusedinmanysectors,likebiomedicine.Non-metallic materials: > Thisfieldiscenterdonadvancedmaterials, includingmulticom-ponent systems with controlled responseandsensorisedintelligentmaterialsthatmayformpartofspecialdeliverysystemsinbio-medicine.Fine chemistry: > Theseactivitiesarebasedon the synthesis of special organic func-tional chemicals that are of interest to thepharmaceutical industry, such as organicand inorganic coupling agents, or interme-diateprecursors forcomplexreactionsandsophisticatedpolymers.

Products, services and/or techno-logies Ontheonehand,L’Urederracooperateswithcompanies and other agents providing stan-dardservices,suchassupportfortheoptimisa-

tionofindustriallinesorproductionproblems,andtorapidlyresolvespecificneeds.On the other hand, L’Urederra develops itsown technologicalactivities thataregenerallyprotectedbypatents. In thebiomedicalarea,a patent titled “Hyperbranched polymers ba-sedoncyclodextrineandpoly(amidoamine)forthecontrolled releaseof insolublemedicines”has been applied for. This invention relatesto controlled release systems for drugs, andin particular it involves the use of hydrophilicpolymers, poly(amidoamines) (PAA), that cancomplex with highly hydrophobic drugs anddissolve inwatervehicles. Inparticular, this isbeing applied to antitumoral drugs, althoughotherdrugtypesareunderstudy,suchasan-tivirals,so that theycanalsobeadministeredbyinjection.In this sector, L’Urederra also participates ina project titled “Multifunctional nanoparticlesfordetectionandtreatmentofbiofilms”(MNP-Biofilms), the main objective of which is thedevelopmentofanewvectorbasedonnanos-phere-encapsulated magnetic nanoparticlestodetectandtreatbacterialbiofilmsproducedby microorganisms, mainly StaphylococcusAureus (S Aureus). The most important taskcarriedoutbyourcenter in thisproject is theproductionof themagneticnanoparticles,ca-rriedoutat thenanoparticleproductionplant.ThisistheonlyinstallationofitstypeinEurope,withacontinuousproductioncapability in therangeof1Kg/h,producingsmallnanoparticles,between7and25nanometres,ofveryhighpu-rityandwithverylittleagglomeration.

Achievements and future prospectsIn terms of achievements in the biomedicalarea, our center has a wealth of experiencein the development of several types of ma-terials and in the preparation of nanoparticledispersions. The materials dealt with includenanoparticles, principally oxides that can bepreparedassimple,complexordoped,nano-compositesoradvancedpolymersfordifferentapplications.

ÁreaIndustrialPerguita,CalleA,nº131210LosArcos(Navarra)T(+34)[email protected]

contact PersonClaudioFernández(CEO)

l’urederra

research center

32 universities and research centers

general descriptionA total of 12,727 students are following oneof the 42 undergraduate degree courses orthe300graduateprogramsofferedbythetenschools, two technical colleges or other cen-tersandinstitutionsthatbelongtotheUniver-sityofNavarra.Thisyear(2010),3,376studentshaveenrolledon undergraduate courses or graduate pro-gramsinoneoftheUniversity’sthreefacultiesintheareaofBiomedicine:Medicine,Pharma-cyandSciences.

The total research expenditure at the Univer-sity amounts to 103.2 M®, 52% coming fromprivate collaborations, 20% obtained throughcompetitivepublicfundingand28%fundedbytheUniversity.TheUniversitycurrentlyhas690on-goingresearchprojects,bothnationalandinternational. InBiomedicine, theR&DcarriedoutattheUniversityofNavarraistightlylinkedtotheactivitiesattheCenterforAppliedMedi-calResearch (CIMA)and theUniversityClinicofNavarra.

Priority areas TheR&DactivitiesinBiomedicineattheUniver-sitycoverabroadrangeoftopics.Theresearchiscarriedoutacrossacademicdisciplinesandwithaclearlypracticalandappliedfocus.Themainareasofresearchinclude:Genetics,Phar-macokinetics and Pharmacodynamics, Drugdelivery,NanotechnologyforTherapyandBio-materials,Genetherapy.

Products, services and/or techno-logies genetics:Genetic researchondifferent typesofLeu- >kemia.Geneticsincellularmechanisms. >

Pharmacokinetic and Pharmacodynamic Modelling:Physiological and mechanistic models to >correlatedrugdosagewithpharmacologicalresponses.Predictionofclinicalresponsetodrugsinthe >differentdevelopmentstages.

Mucosal drug/antigen delivery:Vehiclesfororaldrugadministrationofpoor- >lysolubleandpermeabledrugs.

New adjuvants for vaccines and immuno- >therapythroughthemucosa.

Nanotherapy and biomaterials:Improvementofcontrolled releasesystems >for polymeric and lipidic micro-and nano-particles.Development of non-toxic, biocompatible >andbiodegradablebiomaterials.

gene therapy:Design,developmentandinvitroandinvivo >evaluationofnonviralvectorbasedformula-tionsfortherapeuticgenedelivery.

Achievements and future prospectsSince its inception in 1952, the University ofNavarrahasconsolidated itsbiomedicalR&Dactivities around thediagnosis and treatmentofmajordiseases.Asaresultofthiswork,theUniversityholds14patentsintheareaofdrugdeliveryandcontro-lled release, aswell as patents in the area ofbio-engineering.The University of Navarra’s continuous com-mitment to life sciences and biomedicine isreflected in the projected creation of a seriesof new research infrastructures. The comingyears (until 2015) will see the emergence ofthreenewResearchCenters:CenterforBioen-gineering,Center forNeglectedDiseasesandCenterforNutrigenomicResearch.TheseResearchCenterswilloperate inclosecooperationwiththeUniversityofNavarra,theUniversityClinicandtheCenterforAppliedMe-dicalResearch(CIMA).

TechTransferOffice:InstitutocientíficoTecnológicodeNavarra(ICT)Av.PíoXII5331008Pamplona(Navarra)T(+34)[email protected]

contact PersonFernandodelaPuente(DirectorR&D)

universidad de Navarra

university



general descriptionThe University Clinic of Navarra is a privatehealthcare center owned by the UniversidaddeNavarra.Thisassociationisoneofthemostrelevant characteristicsof theClinica, since itfullycomplementstheexcellentclinicalpracti-cesandpatientattentionwithelementsof re-searchandteaching.TheClinica has over 2.400 employees and itaims to remainat the forefrontofscientific in-novations/progressinordertoofferaleading,innovative and integral medical service. TheClinica is also committed to ongoing trainingandteachingatall levels,fromundergraduatetraining where it works very closely with theSchoolofMedicineattheUniversityofNavarra,tomanyspecializedtrainingprogrammes.

Priority areas As a general hospital, the University Clinic ofNavarra treats all prevalent diseases. Howe-ver, the researchcarriedout focusesstronglyon oncology, cardiovascular diseases, neuro-logicaldiseases,obesityandnutrition, in tightcollaboration with the Schools of Medicine,Pharmacy and Sciences at the University ofNavarra,aswellastheCenterforAppliedMe-dicalResearch (CIMA).TheseclosetiesallowtheClínicatocoverthewholeprocessofthe-rapeuticanddiagnosticproductdevelopment,frombasicR&Dtoclinicalpractice.

Products, services and/or techno-logies Overthecourseofthe lastthreeyears (2008-2010) the Clínica participated in 191 clinicaltrials, collaborating with a large number ofpharmaceuticalcompanies.Almosthalfofthe-setrialswereinthefieldsofMedicalOncology(29.8%) and Hematology (18.3%), althoughdespite this concentration, the trials coveredatotalof27differentmedicalareas, includingCardiology, Neurology, Dermatology, amongothers.Inaddition,theClínicaalsoconductsandpro-motesitsowntrials.Between2008and2010,the entity carried out 13 clinical trials in theareasofInternalMedicine,Hematology,Onco-logy,CardiovascularresearchandNeurology.TheClínicaengagesintrialsatallstagesofde-velopment,rangingfrompilotstudiestophaseIV.Ofthenearly200trials inwhichtheClínicahas participated, Phase I represents 15.2%;

Phase accounts for 38.4%; Phase III covers41.1%,while4%wereconductedinPhaseIV.Approximately 2,700 individuals have partici-patedinthesetrialsoverthelastthreeyears.

The clinical trials in the area ofOncology areparticularly important,andassuch,aspecificunitwithexclusivelydedicatedstaffmanagesthe nearly 60 Oncology related trials carriedout,withtheparticipationofover400patients.

Achievements and future prospectsAsauniversityhospitaltheUniversityClinicofNavarraisdedicatedtoadvancingcurrentme-dicalknowledge.Hence, it isactively involvedin research projects at both the national andinternationallevel,anditparticipatesinvariousthematicnetworks.Asaresult,theUniversityClinicofNavarraoftengenerates industrial property and the entity’sDoctors frequently publish their scientific fin-dingsinhighcaliberinternationalpublications.

Avda.PíoXII3631008Pamplona(Navarra)T(+34)[email protected]

contact PersonGabrielCanel(DirectorR&D)

clínica universidad de Navarra (cuN)Hospital >

support healthcare centers

Healthcare center

34

general descriptionANAIN(InnovationAgencyofNavarra)isapu-bliccompanycreated in1999by theGovern-mentofNavarratopromoteaquantitativeandqualitativeincreaseofinnovationinNavarra.ANAIN employs 11 people and it contributestotheeconomicandsocialdevelopmentoftheregionbypromoting andorganicing activitiesataregional,nationalandinternationallevel.

Priority areas Start-upofnewinnovationprogrammesand >projects.Promotion of collaborative R&D projects >andtheparticipationintheinternationalR&Dspace.Fostering collaboration and coordination >amongAcademia–Technology–Enterpriseentities.Promotion of sectorial competitiveness: >managingclusters,thematicpanels,etc.Technologicaltransferandstrategicwatch >Networksparticipationpromotion. >Awareness and communication of the be- >nefitsofinnovationtotheNavarrasociety.

ANAINworks for: enterprises, clusters, asso-ciations,Universities,ResearchCenters / Ins-titutesandDepartmentsoftheGovernmentofNavarra.

Products, services and/or tech-nologies PreparationandmonitoringofTechnological >PlansforNavarra(theIIITechnologicalPlanforNavarraiscurrentlyinmotion).Coordination of MODERNA, a new eco- >nomicdevelopmentPlanforNavarra,whichinvolves its implementation,monitoringandcontinousupdating.Coordinationofthe“RedTecnológicadeNa- >varra” (RETECNA - Technological NetworkforNavarra).Managementofthe“ParquedelaInnovación >deNavarra”(Navarra´sInnovationPark).Coordinationoftrainingandorganizationof >eventsrelatedtoinnovationandtechnology.Organisationandmanagementofthematic/ >sectorialpanels.Management of the Agro > Food cluster(CLAN).CoordinationoftheBioNavarraStrategy. >

Management of www.navarrainnova.com, >Navarra’sInnovationwebsite.Participationincertainprogrammes,suchas >the EU-funded Euroinnova Navarra, Share-biotechetc.

Achievements and future prospectsANAINisworkingtosituateNavarraamongthemostinnovativeregionsinEurope.

AvenidaCarlosIII,11-1ºdcha.31002Pamplona(Navarra)T(+34)[email protected]

contact PersonMaríaJoséFernándezIraizoz(ProjectManager)

Agencia Navarra de Innovación y Tecnología s.A. (ANAIN) RegionalGovernmentAgency >

Promoting agents



Promoting agents

general descriptionCEIN, the Business Innovation Center in Na-varra, is a regional business innovation agen-cy that provides assistance to prospectiveentrepreneursandSME’sinordertopromoteeconomic development through the creationofenterprises.Withmorethan80employees,CEINencouragesentrepreneuship,helpsstartupprojects todevelopandsupportbusi-nes-ses grow and innovation. CEIN’s philosophyis European-orientated, both in terms of theworkmethodsthat itemploysandintermsoftheconstantsearchforinnovativeservicesandnewbusinessopportunitiesoreconomicdeve-lopment projects in collaboration with otherEuropeanregions.Itsshareholdersaremadeupof45companiesandorganisationsbasedinNavarra,chairedbytheGovernmentofNavarra,whichisthemainshareholder through the region’sDepartmentof Innovation, Entreprise and Employment.Despitehavinga legalstatusofaPublicLimi-tedCompany,CEINisanon-profitmakingor-ganization.

Priority areas The creation and consolidation of biomedicalcompanies.

Products, services and/or tech-nologies Itsmainsupportserviceareasare:Promotion of entrepreneurial values in so- >ciety,specificallyinschools,universitiesandothergroups.Businesscreationsupport:specificservices >fortechnologybasedcompanies.Growth and consolidation of existing com- >panies:training,cooperation,incubatorser-vices.Detectionofnewbusinessopportunitiesfor >Navarra.Innovationpromotionandsupportservices >inorder toenhance thecompetitivenessofregionalcompanies.Training programmes for innovative, effec- >tiveandmodernentrepreneursandSME’s.

Threespecificservicesforthebiomedicalfieldare:

entrepreneurial Project Phase > The objective of this service is to build-uptechnological projects, with suitable profe-

ssional,scientificandtechnologicalsupporttosituatesuchprojectsinthemarket.Inspiredby the most successful European expe-riencesinthisfield,theNavarraTechnology-basedinnovativeEnterprise(EIBT)ProgramsupportsnewEIBTprojectsthatcome intobeinganditactsasa“companion”through-out theentireprocessofcreatingtheEIBT,“bringing together” entities willing to sup-portinnovationandestablishcompanies(www.eibt.es).

Funding: venture capital > CEINmanages two seed funds of venturecapital,with6millioneurostoinvestinnewinnovativeenterpriseprojects.Theservicesoffered include: access to venture capital,search for additional financing (www.cein.es/startup/).

Business Incubator > TheBusinessCenterisbasedatCEIN’sownpremisesonthePolígonoIndustrialMocholí(Noáin) industrial estate, 7 kilometres fromthecityofPamplona.Thecentercoversanareaof4,186m2,dividedintoatotalofthirty-nine 35 and 55m2 offices/business prem-ises,and100to400m2industrialbuildings.

Achievements and future prospectsThesearesomebiomedicalentreprisesinNa-varra that CEIN is working with: 3P Biophar-maceuticals, IDIFARMA, Ojer Pharma, Phar-mamodelling, Bionanoplus and ProRetinaTherapeutics.CEINisalsocurrentlyhelpingtobuildupthreenewbiomedicalenterprises.Anewprogramisbeginningintheareaof“medicalimaging”,mat-chingenterpriseswithuniversitycapabilitiestogeneratenewopportunities.

PolígonoIndustrialMocholí31110Noáin(Navarra)T(+34)[email protected]

contact PersonFernandoBaztán(Dept.ofKnowledgeBasedCompanies)

centro europeo de empresas e Innovación de Navarra - ceIN s.A.RegionalGovernmentAgency >

36

general descriptionClaveMayorisaVentureCapitalmanagementcompany that was founded in June 2002through theactivitiesof its founders formorethan 10 years in “Mergers and Acquisitions”.Thecompanycurrentlyemploys16peopleanditscapitalisentirelyprivate.ClaveMayor has developed an extensive un-derstanding of the Biomedical sector and itnowhasastrong reputationamong those in-volvedinthissector.Similarly,ithasagoodnet-worktostudyanykindofinvestmentproposalworldwide.

Priority areas The financing of Health Sciences companieswith a special interest inBiomedical,MedicalDevicesandDiagnostics.

Products, services and/or tech-nologiesThis venture capital company manages over10 venture capital funds: Arista Viva, Tres aPartner, Agora Mayor, Punto Futuro, RondaTIC, Ronda Innovación, Comval Emprende,RondaViva,RealdeVellónandSeguranza.Indeed, Clavemayor has invested in severalSpanish Biomedical companies: Bionostra,Alma Bioinformatics, IDIFARMA, Vivotecnia,3P Biopharmaceuticals, Ojer Pharma, ViviaBiotech, Clavesuan Desarrollos Biomédicos,ProretinaTherapeutics,GadeaPharmaceuticalGroup, Activery Biotech, Biotica BioquimicaAnalitica,TCDPharma,Hepacyl,Cytognos.RondaVida is the fund that is specificallyde-dicated to the Health Science market. ClaveMayorhasmanagedatotalinvestmentof25Meurosinthisareaofknowledge.

Achievements and future prospectsClaveMayorisreadytolaunchanewFundfullydedicatedtoHealthSciencescompanieswiththegoalofraising100MeurostobeinvestedinSpain,EEUUandtherestofEurope.ClaveMayorwillstartthisfundraisingprocessattheendof2010.

Promoting agents

C/EmilioArrieta,11bis.2°31002Pamplona(Navarra)T(+34)[email protected]

contact PersonRicardoPérez(ManagingDirector)

clave Mayor s.A.Venturecapital >



Promoting agents

general descriptionThe“CorporacciónCAN”wasfoundedinMay2000tomanagetheportfolioofcompaniesinwhichCajaNavarra (CAN), themain financialinstitution of the region, holds stakes, and topromoteitsinterestinnewcompanies.“Corpo-racciónCAN”isnowoneoftheforemostinde-pendentmanagers inSpainand ithasstakesinmore than25companies in its two linesofbusiness: growing companies and emergingcompanies.Thebusinessmodelof“CorporacciónCAN”isfundamentallybasedontakingminoritystakesinunlistedcompanies,cateringforpre-agreeddisinvestment mechanisms to facilitate theactive turnoverof investmentsandaims, andabovealltogeneratevalueinequalityofcondi-tionsforallshareholders.Thus,“CorporacciónCAN” reliesonasetofcomparativeadvanta-ges,themostnoteworthyofwhichincludesfle-xibilitywheninvesting,asthemaininvestororotherwise,andevenco-investmentwithothersimilarinstitutions.“Corporacción CAN” has a unique networkto identify projects and analyse investmentproposals(morethan700projectshavebeenanalysedsinceitscreation).Itexhaustivelymo-nitors thecompanies it holdsstakes inand ithasaproventrackrecordsince2000.Thestrategyof“CorporacciónCAN”istoparti-cipateinbusinessprojectsatallphasesofde-velopment:fromseed/startupstomaturepro-jects,usuallywithventurecapitalasthemostcommonfinancialinstrument.

Priority areas Biomedicalcompaniesfinancing

Products, services and/or tech-nologies CorporacciónCANhasacommittedinvestmenttomorethan50companies,9ofwhichareinthe biotechnological sector. The investmentin biotechnology enters both directly to thecompanies and indirectly through investmentfunds:Direct investment: 3P Biopharmaceuti- >cals,UTECIMA,DignaBiotech, IDIFARMADesarro-lloFarmaceutico,ProyectodeBio-medicinaCIMA-BITA, ProRetina,Neurotec,BioglaneandCbelaya&Mhuget.Indirect investment (VCFundswithbiotech >

investment): Ysios BioFund, Ronda Viva,TaldeCapital.

Achievements and future prospects“Corporacción CAN” considers the medicalBiotechnologysectorahighpriorityinNavarraand would like to increase its holding in themedicalbiotechnologysector.

Avda.CarlosIII,8-6ªplanta31002Pamplona(Navarra)T(+34)948077007www.corporaccioncan.com

contact PersonJuliánAldaz(DirectorofInvestmentanalysis)

corporacción cANVenturecapital >

38 Promoting agents

general descriptionGenerawasfounded in2001andcontributesadded value to the development of SMEs,thanks to the professional experience of itspartners,over20entrepreneursfromdifferentindustrialandservicesectors.Generaoperatesinthesphereofventurecapitalorprivateequi-ty, itsmain goal being to invest excess cashassets inbusinesses, in addition toprovidingtheprofessionalexperienceofall itspartners.Its philosophy goes much further than mereexternal financing, through its undertaking todevelopbusinessinitiativesandcreatevalue.The more than 20 entrepreneurs that makeuptheGenerashareholdinghavewithahighlysuccessful trackrecord intheirrespectivebu-sinesses. They operate in many different in-dustrialareasand theycanbeconsideredasusefulpartnersandnotmerelyinvestors.

Priority areas Cellerix is part of Genera’s portfolio. Cellerixis a biopharmaceutical company founded in2004 thatdevelops innovative treatmentsba-sedoncelltherapy.

PaulinoCaballero4,4ºizda.31002Pamplona(Navarra)T(+34)[email protected]

contact PersonJesúsGonzálezInsausti(CEO)JuanMartínezJoaristi(InvestmentManager)

geNerA - Navarra Iniciativas empresariales s.A. Venturecapital >



Promoting agents

general descriptionSODENA is the key investment instrument oftheGovernmentofNavarraforbusinessdeve-lopment in the region,withmore than300M®committedindifferentinvestments.SODENA carries out its activities as a publiclimitedcompanythatactivelyandprominentlyparticipates in different phases of businessprojectswhichcontributetothebalancedandsustainabledevelopmentofNavarra.Venturecapitalisthemainfinancialinstrumentusedintheseprojects,aconstantfeaturesin-ceSODENAwasconstituted in1984,usuallytakingthepositionofco-investor.SODENAiscomposedof14employeesanditleadsbusinessprojects that private investorsare that are receiving insufficient support butthat are considered strategic, as well as su-pportingandpromotingthegrowthofexistingornewprojects.SODENA also offers support for the interna-tionalisationofcompaniesthatwishtosetupoperations in other countries. In addition, itpromotes projects that consider the environ-ment tobean important factorandsearchesforchannels tohighlightpotentialdeficitsandopportunities thatmayexist inpersonnel trai-ning,aswellasensuringtheavailabilityofcer-taininfrastructures.SODENA´s strategy is to participate in busi-ness projects in all phases of development,from seed/start ups to mature projects, andit considers the Biomedical/BiotechnologicalsectorahighpriorityfortheregionofNavarra.

Priority areas ThestrategicsectorswhereSodenaisgoingtofocusitsinvestmentactivitiesare:Biotechnology. >RenewableEnergy. >Agrifood. >Internationalisation. >Nanotechnologyasacrosssector. >

Products, services and/or tech-nologiesSODENAhasacommittedinvestmentinmorethan47companies,10oftheminthebiotech-nological sector. The biotechnology invest-mentisbothdirectinthecompaniesandindi-rectthroughinvestmentfunds.Direct investment: UTE CIMA, Digna Bio- >tech,ProyectodeBiomedicinaCIMA-BITA,

IDIFARMA, 3P Biopharmaceuticals, OjerPharma, ProRetina Therapeutics, ActiveryBiotech,AlbinMedicalandWasserlab.Indirect investment (VCFundswithbiotech >investment): Ysios BioFund, Suan FarmaBiotech,Inveready,StartupCapitalNavarra,FondoJoven.

Achievements and future prospectsThecompanieswhereSodenainvestsalreadygeneratearound500positionsand thanks toSodena’s continued investment since 1996,Navarracanboastthatithasallthenecessarymeanstocarryoutthefullcycleofdrugdeve-lopment.Sodena’smain strategy for the developmentofbiotechnology isto invest insettingupandmanagingaportfolioofbiotechcompaniesde-votedtothedevelopmentofmoleculesthatwillserveasfuturehumantherapeuticdrugs.

AvenidaCarlosIIIelNoble36,1ºDcha.Pamplona(Navarra)T(+34)[email protected] PersonMªEugeniaLecumberri(InvestmentManager)

sociedad de Desarrollo de Navarra (sODeNA)Venturecapital >

40 Biotechnological core facilities

Biotechnologicalcore facilitiesThe Biomedical sector in Navarra issupported by excellent research andinnovation facilities that can be madeavailable to any interested Biopharma-ceuticalandBiotechnologicalcompanyorresearchinstitution.

Themainbiomedicalfacilitiesandequip-ment available at the universities andresearchcentersinNavarraaredetailedbelow:

Universidad de Navarra (UniversityofNavarra)

UnitofOrganicChemistry:thisunitprovidesservicesas- >sociatedwithmolecularmodelinganddesign.Theunitoffers:

Analytical equipment, with infra-red technology,>MagneticNuclearResonance, spectrophotometers,Chromatographers,amongothers.Molecular modeling equipment, with computing>equipmentandsoftware (Almond2.0.8,Amber8.0;Autodock3.0.5,amongothers).

Pharmacy and Pharmaceutical technology unit: > thisunitoffersservicesassociatedtopre-formulationdesignandstudy,andtheselectionofformulations.Theunitisequipped with analytical equipment, such as spectro-fluorometers,spectrophotometers,gasandliquidchro-matography apparatus (Ultraviolet, Electrochemistry,Fluorescence,Masses),amongothers.Pilot Plant Production unit: > thisunitofferssemi-indus-trialscaleproductionthroughtheuseofdisintegration/dissolutionspeedequipment,microscopes,aswell asotherlaboratoryequipment.Toxicology unit and preclinical pharmacokinetic >studies:thisunitprovidesservicesforstudiesofsafety,securityandefficacy.Theunithasanalyticalequipmentavailable including liquid chromatography and massspectrometryapparatus (AgilentsystemLC/MSDTrapXCT, LC/MSDTOF6220withdual ESI),RRLC,HPLCandgaschromatographyapparatus (AgilentTechnolo-gies1100and1200),aswellasotherbasic laboratoryequipment.Animal facility: > housingawiderangeofanimalspeciesincluding largeanimals,suchasmonkeysandground-hogs.Theanimalfacilityhasatotalof1,425m2ofwhich625m2arecomposedofcleanandmixedareasforro-dents,togetherwith28roomsforhousingand/orwor-kingwithrodents.Theremaining800m2arededicatedtolargeanimalsorfarmanimals(sheep,pigs,miniaturepigsandhybrids,etc.),aswellassomerodents.Thereare7roomsfordifferentanimalssuchasgroundhogsorrabbits,and2roomsforprimates,aswellasananimalsurgeryfacility.

Biomedical Cluster description / Companies 41


Centro de Imagen Médica (CenterforMedicalImaging)

Ultra-high-fieldmagneticresonanceimaging(MRI)equip- >ment(7TeslasMRIforhumans,3TeslasMRIforhumansand11,7TeslasMRIforanimals).Image acquisition equipment at Terahertz frequency >(THz).Cleanroomwithtwoseparateareas,oneformeasure- >ment, characterization and assembly, and another forfine production of Medical Imaging technologies anddevices.Imageandmedicaldatacomputingandstoragecenter >OpticalimagingandElectronicslaboratory. >

Biotechnological core facilities

Centro de Investigación Biomédica - CIB (CenterforBiomedicalResearch)

PharmaceuticalResearchincludingaClinicaltrialmoni- >toring facilitywherePhase II, IIIand IVclinical trialsaremonitored.By2012, theNavarraHealthcareService isexpectedtomanageitsownPhaseIclinicaltrialsUnit.Biobank research Facility: > Brain bank, tumor bankand DNA bank. Since 2009, this biobank has beenassociated with the National BioBank Network (ReT-BioH)anditfunctionsataninternationallevel.Animal Facility of 642 m > 2 distributed into 4 areas:

SPFArea(SpecificPathogenFree)thathas5rooms>forhousingimmunosuppressedornudemice,andaproceduresroom.RodentQuarantinearea.>Conventional housing area for large animals (pigs,>rabbits)andforsmallanimals(rats,mice),includingaproceduresroom.Servicearea:washingarea,changingrooms,stores,>residuesandotherinstallations.

experimental surgery: > thisunithastwoexperimentaloperating theatres that can be accessed remotely byvideo for training,aswellasaPre-andPost-Operativearea.cell Therapy unit: > thisunithasaGMProomthat,aswell as other services on offer, enables it to performcelltherapyassaysinhumansusingmesenchymal,he-matopoieticandcardiaccells.Ithasthreecleanroomsthatcanbeusedforproductionandpackaging.genomic platform: > thisplatformprovidesservicessuchassamplesequencing,thecharacterizationofgeneex-pressionprofilesandbioinformaticsanalysis.Proteomic, Metabolomic and lipidomic platforms: > this unit characterizes protein species and performsqualitycontrolofsuchsamples.Italsoanalysesproteinexpressionprofilesandpost-translationalmodifications.Imaging and Morphology unit: > this unit offersmor-phofunctional services to characterize animal models.Among the equipment available is a confocal micros-copesuitablefortheanalysisoflivingcells,atissuemi-croarrayapparatusandmicrodissector.Biotechnology enterprises Incubator: > thereare500m2 available to house biotechnology companies thatcomplementthetechnologyavailableatthecenter.

42 Biotechnological core facilities

FideNa

Lithography capability for large areas (up to 15 cm > 2)thatcanbeusedforsurfacefunctionalization,toinducebiomoleculeselfassemblyandscaffolding,includinganE-Beam Evaporator, Interference Lithography Equip-mentandReactiveIonEtching.HighResolutionCarlZeissFE-SEMUltraPlus,withlow >voltage and charge compensation for biological sam-ples.Analytical equipment with AFM, Spectro-Photometer, >ZetaSizeramongotherlaboratoryequipment.

Centro de Investigation Médica Aplicada - CIMA(CenterforAppliedMedicalResearch)

Proteomic unit: > thisunitofferslargescaleproteinana-lysis (proteomics),employingproteinseparationmethodsincombinationwithmassspectrometry,andtheseanaly-sescanrangefromtheidentificationofproteinspresentinasampletoacomparisonofproteinexpressionpro-filesbetweendifferentsamples.genomics unit: > thisunitperformsgeneticanalysesin-cludingCGHandgenotyping,aswellas thedesigningandprocessingofexperiments toanalyzegeneexpre-ssionusingAffymetrixTechnology.Imaging unit: > this unit offers support and guidanceregarding theuseof imaging techniquesand in imageanalysis. The unit is well equipped with imaging plat-formsthatcoverthespectrumfromcelltowholeanimalimaging:

Three confocal microscopes –one standard Laser>Scanning Microscope and two Spinning Disk fastconfocalmicroscopesfortimelapseexperiments;Twoautomatedepifluorescencemicroscopesforex->vivoimagingoffixedtissues;X-RaymicroCTtomography forsmall laboratoryani->mals;High resolution ultrasound system for echography>imaging.

L´UrederraAnanoparticleproductionplantcapableofproducing1 >kg/hofhighlypurenanoparticles,mostlyoxides(simple,complexordoped),phosphatesandcarbonates,ofverysmallsizeandwithverylittleagglomeration,sui-tableforuseinbiomedicalapplications.Nanoparticle production equipment with a capacity >toproduce100g/hofawidevarietyofverysmallsizenanopowderswith a narrow distribution, andwith thepossibilityofworkingunderGMPconditionsfortheiruseinsectorssuchasthepharmaceuticalorbiomedicalin-dustry.

Biomedical Cluster description / Companies 43


Biotechnological core facilities

Clínica Universidad de Navarra (UniversityClinicofNavarra)

clinical Pharmacological research unit: > the unit isusedforPhaseIclinicaltrialsandfocusesondrugmoni-toringinthebody.Thelaboratoryhasacapacityforupto12individuals,anditismanagedunderGLPandGCPconditions.Pharmacy and Pilot Production Plant: > thisserviceiscomprisedofaMixtureUnitandaPilotPlantforthepro-ductionofmedicines.cell Therapy laboratory: > thisunitdevelopsadvancedtherapeutic products with special emphasis on He-matopoieticancestorprogram,idiotypicvaccines,adultstemcelltherapy,tissuebanksandcancerimmunothe-rapy.AllproductionfullycomplieswithGMPstandards.radiopharmacy unit: > this unit employs PET techno-logyforinvivopharmacokineticstudiesthatareusedinclinicaltrials,adheringtoGMPstandards.clinical genetics unit: > where genetic alterations re-latedtomedicaldiseasesarestudied,suchascancer,neurodegenerative disorders and cardiovascular di-seases.Aspecificprogramwasinitiallysetuptodetectgeneticpredispositionforbreastandovariancancer,aswell as aprogram for the early detectionof hereditarycoloncancer.experimental surgery: > incompliancewithallexistinglegislation, this facilityprovidespractical training for fu-ture professionals and further services that support tothepre-clinicalresearchconductedattheClínica,aswellasinotherprivateorpublicentities.3TeslAs - radiomagnetic resonance: > this state-of-the-art installation isusedboth for treatmentandre-search,anditenablestheClínicatocarryoutadvancedimagingstudies,particularlyintheareaofneurology.

Area EIBT - Parque de la Innovación de Navarra Technology-BasedInnovativeEnterprisearea-Navarra´sInnovationPark

Spacetoaccommodatestart-upcompanies:thereare >offices/businesspremisesof35and55m2,andincuba-tor spacesof100 to400m2,all availableonaglobalsiteof4,186m2.Allthepremisesareequippedwiththeirownwaterandelectricitysupplies,telephones,Internetaccess, heating, 24/7 security system, etc. meaningthatassoonasacompanymoves in itcangetdowntowork.Business development, support and mentoring ser- >vices,aswellasaccesstofunding,businessguidanceandtrainingprogramstailoredtotheneedsofbiotechcompanies.

Biomedicine in Navarra 2010

Documents

Transcript of Biomedicine in Navarra 2010